Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. 2012

Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway. tone.gretland@netcom.no

BACKGROUND The association of early-onset posttransplantation hyperglycemia with long-term renal allograft survival is unknown. METHODS Seventy-one (SD 9) days after transplantation, 1410 first-time kidney transplant recipients without diabetes underwent an oral glucose tolerance test and were observed until primary outcome (graft loss) or December 31, 2008 (median [range], 6.0 years [0.3-13.8 years]). We used multivariable Cox regression analysis adjusted for age, gender, body mass index, creatinine level, donor age, preemptive transplantation, deceased donor, early rejection, and early cytomegalovirus infection to estimate hazard ratios for overall and death-censored allograft survival. RESULTS A total of 392 (28%) recipients experienced graft failure, and 235 (60%) were induced by death. Each 1 mmol/L increase in 2-hr plasma glucose (2hPG) was associated with 7% and 3% increased risk of unadjusted and adjusted overall graft failure (hazard ratio [95% confidence interval], 1.07 [1.04-1.10] and 1.03 [1.00-1.07]). Fasting plasma glucose was associated with unadjusted but not adjusted overall graft failure (1.09 [1.01-1.18] and 1.07 [0.98-1.17]). Neither 2hPG nor fasting plasma glucose was associated with death-censored graft loss (P=0.578 and P=0.896). Compared with recipients with normal glucose tolerance, recipients with posttransplantation diabetes mellitus showed a tendency toward increased overall multiadjusted graft failure (1.30 [0.98-1.73]). This was not observed in patients with impaired fasting glucose or impaired glucose tolerance. CONCLUSIONS In this study, 2hPG was associated with overall graft failure but not death-censored graft failure. The link between 2hPG and graft failure may be explained by the association with mortality.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009664 Norway A country located in northern Europe, bordering the North Sea and the Atlantic Ocean, west of Sweden. The capital is Oslo. Kingdom of Norway
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
January 2023, American journal of nephrology,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
June 2021, Pediatric transplantation,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
June 2010, NDT plus,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
November 2012, Transplantation proceedings,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
January 2019, Acta haematologica,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
December 2019, Revista medica del Instituto Mexicano del Seguro Social,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
July 2012, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
October 1999, Clinical transplantation,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
February 2020, Journal of clinical medicine,
Tone G Valderhaug, and Jøran Hjelmesæth, and Trond Jenssen, and Jo Røislien, and Torbjørn Leivestad, and Anders Hartmann
October 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Copied contents to your clipboard!